Proof-of-Principle Data for Proprietary CobaCyte™ Platform in siRNA
Dallas, TX and New York, NY, September 29, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced today that it has made significant progress with its proprietary Cobalamin-targeted drug-delivery program for siRNA therapies. As a result of the continued advancements made with its Cobalamin program, Access rebranded the targeted-drug delivery technology as CobaCyte™; and submitted additional patent applications for its improved CobaCyte formulations, including siRNA compositions.
Over the past months, Access’ CobaCyte siRNA application has shown significant promise. In an in vitro siRNA transfection dose-response study, Access’ CobaCyte nanoparticle carriers loaded with an apoptosis-inducing siRNA molecule showed transfection activity in hard-to-transfect cell lines with potentially better toxicity profiles compared to other reagents. Further studies including in vivo gene-knockdown studies are planned. Additionally, Access has initiated a program whereby proprietary formulations of currently marketed chemotherapies will be developed and tested to assess CobaCyte’s ability to enhance drug pharmacokinetics and pharmacodynamics.
Read more »
Sub-license to JianAn Pharmaceuticals Provides Extensive Infrastructure to Support Sales and Marketing of MuGard in China
DALLAS, TX and NEW YORK, NY, September 21, 2010
Access Pharmaceuticals, Inc. (OTC BB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc. (“RHEI”), a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories. Coinciding with the signing of the above agreement, Access also approved a sub-license agreement between RHEI Pharmaceuticals and Jian An Pharmaceuticals (“Jian An”) Limited in Shenzhen, China in an effort to leverage Jian An’s extensive sales, marketing and regulatory infrastructure for the launch of MuGard in China and Taiwan.
Jian An is headquartered in Shenzhen, China and has a 25-year history of selling pharmaceutical and other medical products in the China market. Jian An has 1400 sales representatives covering all majors centers in China through 169 sales offices. With Jian An’s sales and marketing infrastructure and the supply agreement which will provide up to $30 million of MuGard to the territory, Access Pharmaceuticals’ commercialization efforts remain on track in China and its other South East Asian territories. Access retains its existing milestone and royalty structure for the territory. In addition, Access and RHEI have also filed a new patent application in China covering MuGard for the relief and reduction of erythema. This new application is expected to provide additional IP protection as well as the potential for a new indication for MuGard.
Read more »
Dallas, TX and New York, NY, September 16, 2010
Access Pharmaceuticals, Inc. (OTCBB: ACCP) was among the presenters at this year’s Rodman & Renshaw Annual Global Investment Conference in New York City. Access’ CEO Jeffrey B. Davis’ presentation along with a slideshow is now available online at: http://www.wsw.com/webcast/rrshq18/accp.
This presentation contains certain statements that may be forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including statements relating to the product portfolio and pipeline and clinical programs of the combined company, the market opportunities for MuGard™, the sales of, market opportunities for and planned studies of ProLindac™, the market opportunities for Thiarabine and the Cobalamin programs, and the combined company’s goals and objectives. These statements are subject to numerous risks and uncertainties, including but not limited to the risks detailed in Access’s Annual Report on Form 10-KSB for the year ended December 31, 2009, and other reports filed by the companies with the Securities and Exchange Commission.
These materials are not an offer to sell securities and are not soliciting an offer to buy securities.
MuGard, First Day Every Day – Designed To Help Cancer Patients And Caregivers
DALLAS, TX and New York, NY September 15, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has launched www.MuGard.com. The patient- and healthcare professional- focused site is a comprehensive resource offering educational material on oral mucositis, patient analysis, MuGard product and how-to-order information.
“We are proud to have launched our product website as it is a resource for patients and healthcare professionals,” said Frank Jacobucci, VP of Sales and Marketing for Access Pharmaceuticals, Inc. He continued, “Keeping the patient in mind, we constructed an easy-to-navigate MuGard destination where both patients and doctors can go to learn about oral mucositis, symptoms and the benefit that MuGard provides someone undergoing radiation and chemotherapy for various types of cancers, including head and neck cancers, such as throat cancer. By starting MuGard on the first day of anticancer regimens, as shown in the clinical data, a significant number of patients can significantly reduce the occurrence, duration and severity of oral mucositis. MuGard – first day, every day.”
Read more »
Company To Ship Over $700,000 Of MuGard To Distribution Partner for Initial Live-Pharmacy And Online Inventory Demand
DALLAS, TX and New York, NY September 14, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has received its first commercial order for MuGard from BioScrip (Nasdaq: BIOS), its specialty distribution partner. BioScrip’s initial purchase order of MuGard, totaling over $700,000, will provide adequate inventory for its various distribution channels to support the Company’s first phase of its product launch for MuGard. Access Pharmaceuticals has inventory on hand and will begin shipping product to BioScrip immediately. MuGard is an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiation and/or chemotherapy.
Read more »
Company Presentation to be Held on Tuesday, September 14th at 9:35AM ET at The New York Palace Hotel
DALLAS, TX and NEW YORK, NY, September 8, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer, supportive care, today announced that the Company will present at the Rodman & Renshaw Annual Healthcare Conference in New York City on Tuesday, September 14th at 9:35AM ET in the Fahnestock Salon, located on the 5th floor of the New York Palace Hotel.
On Tuesday, Jeffrey Davis, Chief Executive Officer of Access Pharmaceuticals, will give a presentation on the Company’s commercial launch of its lead product, MuGard and detail the development strategy for ongoing programs within its drug pipeline. A live webcast of the presentation may be accessed by clicking on the following link: http://www.wsw.com/webcast/rrshq18/accp . A replay of the presentation will be archived and may be accessed under the investor relations section of the company’s website, www.accesspharma.com.Management will be available to meet with investors or licensing partners September 13-15. To arrange a one-on-one meeting with Access management at the conference, please email Christine Berni, christine.berni@accesspharma.com.
Read more »
Digg!
Del.icio.us
MuGard's ready-to-use viscous liquid is tasteless, and is safe to swallow. See